Interleukin 15: Biology and relevance to human disease

Blood

Volumn 97, Issue 1, 2001, Pages 14-32

  Fehniger, Todd A ^a   Caligiuri, Michael A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; IRINOTECAN; RECOMBINANT INTERLEUKIN 15;

CYTOKINE PRODUCTION; DIARRHEA; ENTERITIS; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN TISSUE; IMMUNOPATHOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; STOMATITIS; WEIGHT REDUCTION;

EID: 0035169507     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.1.14     Document Type: Review

References (286)

1. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor
2. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells
3. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells
4. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region/IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation
5. Haemopoietic receptors and helical cytokines
6. Structural design and molecular evolution of a cytokine receptor superfamily
7. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor
8. Reversible defects in natural killer and memory CD8 T cell lineages in IL-15 deficient mice
9. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation
10. Chromosomal assignment and genomic structure of IL-15
11. Genomic structure and chromosomal localization of the human interleukin 15 gene (IL-15)
12. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines
13. Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms
14. Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides
15. Translational efficiency is up-regulated by alternative exon in murine IL-15 mRNA
16. Alternative splicing of mouse IL-15 is due to the use of an internal splice site in exon 5
17. Gene for T-cell growth factor: Location on human chromosome 4q and feline BI
18. Interleukin-2: Inception, impact, and implications
19. Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion: Role of different signal peptides
20. Differential intracellular trafficking, secretion, and endosomal localization of two IL-15 isoforms
21. The long signal peptide isoform and its alternative processing direct the intracellular trafficking of IL-15
22. Differential roles of interleukin 15 mRNA isoforms generated by alternative splicing in immune responses in vivo
23. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling
24. The IL-2 receptor complex: Its structure, function, and target genes
25. Interleukin-2, interleukin-15, and their receptors
26. The structure and function of gamma c-dependent cytokines and receptors: Regulation of T lymphocyte development and homeostasis
27. X-linked SCID and other defects of cytokine pathways
28. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15
29. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor
30. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes
31. Natural splicing of exon 2 of human interleukin-15 receptor alpha-chain mRNA results in a shortened form with a distinct pattern of expression
32. Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex
33. Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells
34. Common cytokine receptor gamma chain (gamma c)-dependent cytokines: Understanding in vivo functions by gene targeting
35. Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development
36. Natural killer and T cells of innate and adaptive immunity: Lymphoid compartments with different requirements for common gamma chain-dependent cytokines
37. The structure and function of gamma c-dependent cytokines and receptors: Regulation of T lymphocyte development and homeostasis
38. Multiple gamma c-dependent cytokines regulate T-cell development
39. IL-2 signaling involves recruitment and activation of multiple protein tyrosine kinases by the IL-2 receptor
40. Signaling through the hematopoietic cytokine receptors
41. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits
42. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15
43. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation
44. Interleukin-15 (IL-15) induces NF-kappaB activation and IL-8 production in human neutrophils
45. Interleukin-15 signals T84 colonic epithelial cells in the absence of the interleukin-2 receptor beta-chain
46. IL-15: A pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels
47. Interleukin-15 induces rapid tyrosine-phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells
48. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro
49. Induction and regulation of IL-15 expression in murine macrophages
50. Interleukin-15 mRNA is expressed by human keratinocytes, Langerhans cells, and blood-derived dendritic cells and is downregulated by ultraviolet B radiation
51. Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells: A role for IL-15 in attraction of T cells
52. + hematopoietic progenitor cells
53. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells
54. Cytokine gene expression in murine fetal intestine: Potential for extrathymic T cell development
55. Ultraviolet B radiation up-regulates the expression of IL-15 in human skin
56. Requirement of the IL-2 receptor beta chain for the development of Vgamma3 dendritic epidermal T cells
57. Expression of interleukin-15 and its receptor by human fetal retinal pigment epithelial cells
58. Intestinal epithelial cells both express and respond to interleukin 15
59. Interleukin-15, a leukocyte activator and growth factor, is produced by cortical tubular epithelial cells
60. Interleukin-15 gene expression in human astrocytes and microglia in culture
61. Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site
62. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens
63. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells
64. The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1 + T) cells, natural killer cells, and intestinal intraepithelial T cells
65. The NF-kappaB binding site is essential for transcriptional activation of the IL-15 gene
66. Regulation of translation in eukaryotic systems
67. The 5′ untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control
68. Fatal leukemia in interleukin-15 transgenic mice follows early expansions in NK and memory-phenotype CD8+ T cells
69. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15
70. Differential expression of interleukin-15 isoforms in resting human PBMC
71. A potential role for interleukin-15 in the regulation of human natural killer cell survival
72. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15
73. The instructive role of innate immunity in the acquired immune response
74. Biology of natural killer cells
75. Biology and clinical relevance of human natural killer cells
76. The role of natural killer cells in innate resistance to infection
77. Effects of IL-12 on immune responses to microbial infections: A key mediator in regulating disease outcome
78. Activation and function of natural killer cell responses during viral infections
79. Role of natural killer cells in innate resistance to protozoan infections
80. Cytokines acting on or secreted by macrophages during intracellular infection (IL-15, IL-12, IFN-gamma)
81. Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors
82. Development and tolerance of natural killer cells
83. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice
84. Mechanisms of genetic resistance to Friend virus leukemia in mice. I. Role of 89-Sr-sensitive effector cells responsible for rejection of bone marrow allografts
85. Natural killer cells in mice treated with 89strontium: Normal target-binding cell numbers but inability to kill even after interferon administration
86. Natural killer cells, bone, and the bone marrow: Studies in estrogen-treated mice and in congenitally osteopetrotic (mi/mi) mice
87. Production and differentiation of NK lineage cells in long-term bone marrow cultures in the absence of exogenous growth factors
88. Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells
89. Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors
90. The generation of human natural killer cells from CD34+/DR-primitive progenitors in long-term bone marrow culture
91. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: Identification of a CD34+7+ NK progenitor
92. Administration of recombinant interleukin 2 to mice enhances production of hemopoietic and natural killer cells
93. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo
94. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2
95. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity
96. Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity
97. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity
98. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies
99. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting
100. Immune responses in interleukin-2-deficient mice
101. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain
102. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans
103. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain
104. Defective expression of the interleukin-2/interleukin-15 receptor β subunit leads to a natural killer cell deficient form of SCID
105. c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
106. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15
107. Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells
108. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions
109. Fetal liver contains committed NK progenitors, but is not a site for development of CD34+ cells into T cells
110. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: Selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor
111. Cord blood CD16+56-cells with low lytic activity are possible precursors of mature natural killer cells
112. Enhanced survival and potent expansion of the natural killer cell population of HIV-infected individuals by exogenous interleukin-15
113. Identification of a common T/natural killer cell progenitor in human fetal thymus
114. Natural killer cell differentiation: Insights from knockout and transgenic mouse models and in vitro systems
115. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells
116. Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: Definition of cytokine requirements and developmental intermediates
117. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells
118. Functional dissection of the cytoplasmic subregions of the IL-2 receptor beta chain in primary lymphocyte populations
119. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain
120. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice
121. Defective lymphoid development in mice lacking Jak3
122. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses
123. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity
124. The Ets-1 transcription factor is required for the development of natural killer cells in mice
125. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: Comparison with interleukin-2
126. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: The potential role of NK cell subpopulations
127. Immune regulation: A critical link between NK cells and CTLs
128. Human herpesvirus-6 enhances natural killer cell cytotoxicity via IL-15
129. Enhancement of natural killer cell cytotoxicity by the human herpesvirus-7 via IL-15 induction
130. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response
131. Costimulation of human natural killer cells is required for optimal interferon gamma (IFN-γ) production
132. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response
133. IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-γ production in vivo
134. IL-15 is a novel growth factor for murine gamma delta T cells induced by Salmonella infection
135. Interleukin-15 induces antimicrobial activity after release by Cryptococcus neoformans-stimulated monocytes
136. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines
137. Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection
138. C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells
139. Macrophage inflammatory protein 1 modulates macrophage function
140. Granulated lymphoid cells of the pregnant uterus: Morphological and functional features
141. CD3- leukocytes present in the human uterus during early placentation: Phenotypic and morphological characterization of the CD56++ population
142. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua
143. Human uterine natural killer cells
144. The involvement of interleukin (IL)-15 in regulating the differentiation of granulated metrial gland cells in mouse pregnant uterus
145. Granzymes D, E, F, and G, are regulated through pregnancy and by IL-2 and IL-15 in granulated metrial gland cells
146. IL-15, a novel cytokine produced by human fetal membranes, is elevated in preterm labor
147. Human decidual natural killer cells express the receptor for and respond to the cytokine interleukin 15
148. Expression of interleukin-15 in human endometrium and decidua
149. Expression and role of p75 interleukin 2 receptor on human monocytes
150. The gamma subunit of the interleukin-2 receptor is expressed in human monocytes and modulated by interleukin-2, interferon gamma, and transforming growth factor beta 1
151. IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production: Evidence for differential receptor subunit utilization associated with stimulation or inhibition
152. Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2
153. Expression of interleukin-2 receptor γ chain on human neutrophils
154. Interleukin-2 receptor γ chain expression on resting and activated lymphoid cells
155. Interleukin-15 activates proinflammatory and antimicrobial functions in polymorphonuclear cells
156. Human neutrophils express the interleukin-15 receptor alpha chain (IL-15Ralpha) but not the IL-9Ralpha component
157. Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: Modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15
158. The immunobiology of T cells with invariant gamma delta antigen receptors
159. In utero treatment with monoclonal antibody to IL-2 receptor beta-chain completely abrogates development of Thy-1+ dendritic epidermal cells
160. Development and function of the immune system in mice with targeted disruption of the interluekin-2 gene
161. Interleukin (IL)-15 promotes the growth of murine epidermal gamma delta T cells by a mechanism involving the beta- and gamma c-chains of the IL-2 receptor
162. Regulatory function for murine intraepithelial lymphocytes. Two subsets of CD3+, T cell receptor-1+ intraepithelial lymphocyte T cells abrogate oral tolerance
163. Gut intraepithelial T lymphocytes
164. Thymus independent T cell development and selection in the intestinal epithelium
165. Rapid killing of murine lymph node T blasts by intestinal intraepithelial lymphocytes in vitro
166. Extrathymic T cell differentiation
167. Interleukin-15 preferentially promotes the growth of intestinal intraepithelial lymphocytes bearing gamma delta T cell receptor in mice
168. Interleukin-15 may be responsible for early activation of intestinal intraepithelial lymphocytes after oral infection with Listeria monocytogenes in rats
169. IL-15 promotes survival but not effector function differentiation of CD8+ TCRalphabeta+ intestinal intraepithelial lymphocytes
170. Interleukin 15 is a potent stimulant of intraepithelial lymphocytes
171. Human gamma delta T cell subset-proliferative response to malarial antigen in vitro depends on CD4+ T cells or cytokines that signal through components of the IL-2R
172. IL-15 enhances the response of human gamma delta T cells to nonpeptide microbial antigens
173. Protective roles of gamma delta T cells and interleukin-15 in Escherichia coli infection in mice
174. Mouse CD1-specific NK1 T cells: Development, specificity, and function
175. Development and function of natural killer 1 + T-cells
176. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype
177. Human CD3+ T lymphocytes that express neither CD4 nor CD8 antigens
178. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells
179. Role for IL-15/IL-15 receptor beta-chain in natural killer 1.1 + T cell receptor-alpha beta+ cell development
180. Distinct roles for signals relayed through the common cytokine receptor gamma chain and interleukin 7 receptor alpha chain in natural T cell development
181. Activation of naive and memory T cells by interleukin-15
182. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes
183. IL-15 induces the release of soluble IL-2Ralpha from human peripheral blood mononuclear cells
184. Differential regulation of human T lymphoblast functions by IL-2 and IL-15
185. HLA class I-specific inhibitory receptors in human T lymphocytes: Interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells
186. Interleukin-15 up-regulates interleukin-2 receptor alpha chain but down-ragulates its own high-affinity binding sites on human T and B cells
187. Interleukin-15 protects from lethal apoptosis in vivo
188. Chemoattraction of human blood T lymphocytes by interleukin-15
189. IL-15 induces the expression of chemokines and their receptors in T lymphocytes
190. Interleukin 15 induces endothelial hyaluronan expression in vitro and promotes activated T cell extravasation through a CD44-dependent pathway in vivo
191. Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells
192. IL-15 promotes IL-12 production by human monocytes via T cell-dependent contact and may contribute to IL-12-mediated IFN-gamma secretion by CD4+ T cells in the absence of TCR ligation
193. IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice
194. High-dose IL-2 and IL-15 enhance the in vitro priming of naive CD4+ T cells for IFN-gamma but have differential effects on priming for IL-4
195. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens
196. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model
197. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine
198. Interleukin-15 differentially enhances the expression of interferon-gamma and interleukin-4 in activated human (CD4+) T lymphocytes
199. IL-15 promotes cytokine production of human T helper cells
200. IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL2-IgG2b fusion protein inhibits both
201. Interleukin-15: A novel anabolic cytokine for skeletal muscle
202. Interleukin-15 stimulates C2 skeletal myoblast differentiation
203. Interleukin-15 promotes angiogenesis in vivo
204. Role of cytokines in rheumatoid arthritis
205. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis
206. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis
207. The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines
208. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
209. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism
210. A proinflammatory role for IL-18 in rheumatoid arthritis
211. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis
212. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology
213. Cytokines in sarcoidosis
214. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis
215. New insights into the immunopathology of chronic inflammatory bowel disease
216. Increased numbers of interleukin-15-expressing cells in active ulcerative colitis
217. Interleukin 15 activity in the rectal mucosa of inflammatory bowel disease
218. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production
219. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease
220. IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS)
221. Levels of interleukin-15-expressing blood mononuclear cells are elevated in multiple sclerosis
222. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system
223. Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15
224. Transplantation immunology
225. Intragraft IL-15 transcripts are increased in human renal allograft rejection
226. Increased intragraft IL-15 mRNA expression after liver transplantation
227. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans
228. Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation
229. IL-2 and IL-4 double knockout mice reject islet allografts: A role for novel T cell growth factors in allograft rejection
230. Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia
231. Interleukin-2 receptor-inducing factor(s) in adult T cell leukemia
232. Interleukin-15 (IL-15) can replace the IL-2 signal in IL-2-dependent adult T-cell leukemia (ATL) cell lines: Expression of IL-15 receptor alpha on ATL cells
233. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells
234. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins
235. Pathology of cutaneous T-cell lymphoma
236. Interleukin-7 is a growth factor for Sezary lymphoma cells
237. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: Potential autocrine or paracrine effectors in the Sezary syndrome
238. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2
239. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells
240. Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of myc, jun, and novel myc-like proteins in cutaneous T-cell lymphoma cells
241. HTLV-1-like particles and HTLV-1-related DNA sequences in an unambiguous case of Sezary syndrome
242. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice
243. Effects of the deregulated expression of human interleukin-2 in transgenic mice
244. Large granular lymphocytosis
245. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes
246. Aggressive natural killer-like T-cell malignancy with leukemic presentation following solid organ transplantation
247. Aggressive cutaneous NK and NK-like T-cell lymphomas: Clinicopathologic, immunohistochemical, and molecular analyses of 12 cases
248. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation
249. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferafive disorders
250. Interleukin (IL)-15 induces survival and proliferation of the growth factor-dependent acute myeloid leukemia M-07e through the IL-2 receptor beta/gamma
251. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma
252. Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma
253. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops
254. Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer
255. Cytokine interactions in human immunodeficiency virus-infected individuals: Roles of interleukin (IL)-2, IL-12, and IL-15
256. Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression
257. IL-15 stimulates the expansion of AIDS virus-specific CTL
258. In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1 infected patients
259. IL-15 enhances immune functions during HIV infection
260. Interleukin-15 triggers activation and growth of the CD8 T-cell pool in extravascular tissues of patients with acquired immunodeficiency syndrome
261. CD8 T-cell infiltration in extravascular tissues of patients with human immunodeficiency virus infection. Interleukin-15 upmodulates costimulatory pathways involved in the antigen-presenting cells-T-cell interaction
262. Differential effects of interleukin-12, interleukin-15, and interleukin-2 on human immunodeficiency virus type 1 replication in vitro
263. Induction of HIV-1 replication by type 1-like cytokines, interleukin (IL)-12 and IL-15: Effect on viral transcriptional activation, cellular proliferation, and endogenous cytokine production
264. Human immunodeficiency virus (HIV) type-1 GP120-specific cell-mediated cytotoxicity (CMC) and natural killer (NK) activity in HIV-infected (HIV+) subjects: Enhancement with interleukin-2 (IL-2), IL-12, and IL-15
265. Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: Implications for therapy with a monoclonal antibody directed to the IL-2/15Rbeta receptor
266. Interleukin-15 as an activator of natural killer cell-mediated antiviral response
267. Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis
268. The effects of interleukin-15 on human gammadelta T cell responses to Plasmodium falciparum in vitro
269. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells
270. Gamma-interferon: The match that lights the fire?
271. Shwartzman reaction
272. Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction
273. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice
274. Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury
275. Adjuvant therapy of colon cancer
276. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer
277. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model
278. Blood: New designs for a new millennium
279. Differences in pharmacokinetics and biodistribution between interleukin-2 and interleukin-15
280. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
281. Etanercept: Therapeutic use in patients with rheumatoid arthritis
282. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity
283. Interleukin 15: A proinflammatory role in rheumatoid arthritis synovitis
284. Unraveling the structure of IL-2
285. Targeted disruption of the flt3 ligand gene in mice affects multiple hematopoietic lineages, including natural killer cells, B lymphocytes, and dendritic cells
286. The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells